98%
921
2 minutes
20
GRB2 is an adaptor protein which interacts with phosphorylated TGF-β receptor and is critical for mammary tumour growth. We found that TGF-β1-induced EMT increased GRB2 expression in A549 cells (non-small cell lung cancer). Overexpression of GRB2 (A549) enhanced cell invasion while knocking down GRB2 (A549) reduced cell migration and invasion, probably due to increased vinculin and reduced Paxillin patches in A549 cell. TGF-β1-induced EMT was more pronounced in A549 cells and attenuated in A549 cells. This could be due to the reduced expression of E-cadherin in A549 and increased expression of E-cadherin in A549 cells, even before TGF-β1 stimulation. Expression of SNAIL was elevated in A549 cells and was further enhanced by TGF-β1 stimulation, suggesting that GRB2 down-regulates E-cadherin by enhancing the expression of SNAIL. The N-SH3 domain of GRB2 was critical for suppressing E-cadherin expression, while the C-SH3 domain of GRB2 mediating interaction with proteins such as N-WASP was critical for promoting invasion, and the SH2 domain was critical for suppressing E-cadherin expression and invasion. Thus, our data suggests that GRB2 enhances EMT by suppressing E-cadherin expression and promoting invasion probably through N-WASP to promote metastasis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116178 | PMC |
http://dx.doi.org/10.3390/cells7080097 | DOI Listing |
PLoS One
September 2025
Biobank of Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.
Heart failure (HF) and lung cancer (LC) often coexist, yet their shared molecular mechanisms are unclear. We analyzed transcriptome data from the NCBI Gene Expression Omnibus (GEO) database (GSE141910, GSE57338) to identify 346 HF‑related differentially expressed genes (DEGs), then combined weighted gene co-expression network analysis (WGCNA) pinpointed 70 hub candidates. Further screening of these 70 hub candidates in TCGA lung cancer cohorts via LASSO, Random Forest, and multivariate Cox regression suggested CYP4B1 as the only independent prognostic marker.
View Article and Find Full Text PDFKaohsiung J Med Sci
September 2025
Department of Medical Oncology, Haikou People's Hospital, Haikou, Hainan, People's Republic of China.
Inhibition of cuproptosis contributes to the development of non-small cell lung cancer (NSCLC). The expression of RNA-binding motif protein 15 (RBM15) is upregulated in NSCLC. Nonetheless, its relationship with cuproptosis remains unclear.
View Article and Find Full Text PDFLab Chip
September 2025
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA.
CRISPR technology offers an entirely new approach to therapeutic development because it can target specific nucleotide sequences with high specificity, however, preclinical animal models are not useful for evaluation of their efficacy and potential off-target effects because of high gene sequence variations between animals and humans. Here, we explored the potential of using the CRISPR effector Cas13 to develop a new therapeutic approach for influenza A virus (IAV) infections based on its ability to specifically and robustly cleave single-strand viral RNA using a complementary CRISPR RNA (crRNA). We engineered crRNAs to target highly conserved regions in the IAV genome to create a potential pan-viral treatment strategy.
View Article and Find Full Text PDFJ Appl Toxicol
September 2025
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
Graphene oxide and its derivatives have unique physical and chemical properties with applications in many different fields. However, their biological effects and mechanisms of intracellular toxicity have not been completely clarified. In this study, we investigated the cytotoxic and autophagic activities of graphene oxide and its derivatives in A549 human lung carcinoma cells.
View Article and Find Full Text PDFCisplatin resistance significantly limits the efficacy of chemotherapy in non-small cell lung cancer, necessitating the development of new strategies to overcome this barrier. This in vitro study aimed to elucidate the mechanism by which β-Ele reverses cisplatin resistance in lung adenocarcinoma cells via the LINC00511-mediated glycolysis and Wnt/β-catenin signaling pathways. The cisplatin-resistant human lung adenocarcinoma cell line (A549/DDP), with either LINC00511 overexpression or knockdown, was established through plasmid transfection.
View Article and Find Full Text PDF